The Premier Conference on Biomarkers of Aging for Longer and Healthier Lifespan
The Biomarkers of Aging Consortium is bringing together academic and industry leaders to share and discuss the latest advancements in biomarker development for predicting, improving and extending human lifespan.
Join our full-day, in-person event on December 4th 2023 at the scenic Buck Institute in Novato, California to help provide solid ground for our collective longevity R&D efforts. Our event will include a keynote lecture, short talks, panel discussions, as well as poster presentations from leading academic and industry scientists.
Key themes of the symposium:
- Conceptual frameworks and theories of aging and biomarkers of aging
- Assessment and validation of biomarkers of aging
- Application of biomarkers of aging for identification and evaluation of longevity interventions
- Challenges and opportunities for establishing reliable biomarkers of aging
Join Us To Make History
After years of community effort, anti-aging treatments will finally be coming to market in the near future. Yet we still lack standardized, clinically-validated tools to measure the aging process and quantitatively assess the impact of healthspan-extending interventions in humans. As our industry grows, standards are of paramount import.
Our dynamic, full-day symposium will be uniquely focused on sharing the latest research on biomarkers of aging, discussing the key issues we face in moving forward as a field, and defining priorities of the Consortium for the upcoming year.
Confirmed Participants (Speakers, Panelists, & Moderators) (A-Z)
Check out our world-class roster of pioneers. Updated on May 4th 2023.
Nir Barzilai, MD
Director of The Einstein Institute for Aging Research, Albert Einstein College of Medicine
Dr. Barzilai is a Chaired Professor of Medicine and Genetics as well as the Director of The Einstein Institute for Aging Research, the largest center in the world to study the Biology of Aging. He leads the TAME (Targeting/Taming Aging with Metformin) multi-central study to prove the concept that multi-morbidities of aging can be delayed in humans and to change the FDA indications to allow for next generation interventions.
Daniel Belsky, PhD
Assistant Professor of Epidemiology, Columbia University Mailman School of Public Health and Butler Columbia Aging Center
Dr. Belsky's work focuses on reducing social inequalities in aging outcomes in the US and beyond. His research seeks to understand how genes and environments combine to shape health across the life course. His aim is to identify targets for policy and clinical interventions to promote positive development in early life and extend healthspan.
Brian Chen, PhD, MPH
Chief Scientific Officer, FOXO Technologies
Dr. Chen is the Chief Science Officer at FOXO Technologies, specializing in epigenetic technology for assessing human health and aging. He combines his expertise in epidemiology, bioinformatics, and machine learning to discover and validate biomarkers, publishing extensively on aging rates, genetic analysis, and epigenetic clock studies.
Alan Cohen, PhD
Founder and CEO, Oken Health & Associate Professor, Columbia University
Dr. Cohen, an Associate Professor at Columbia University, specializes in elucidating integrative biological processes and identifying reliable biomarkers of aging, health, and system integrity. Through the analysis of epidemiological data, his research contributes to a deeper understanding of health, aging, and longevity at multiple levels.
Alexander (Zan) Fleming, MD
Co-Founder and Executive Chairman, Kinexum
Dr. Fleming, the founder of Kinexum and a prominent figure in endocrinology, coined the term Metabesity to encompass the metabolic commonalities among cancer, chronic diseases, and aging. With notable achievements at the FDA and extensive involvement in biomarker initiatives and regulatory discussions, he is dedicated to advancing healthspan products and promoting healthy aging through conferences like the Targeting Healthy Longevity Conference.
Luigi Ferrucci, MD, PhD
Chief of the Longitudinal Studies Section, National Institute of Aging
Dr. Ferrucci, the Scientific Director of the National Institute on Aging (NIA), conducts research on the pathways of physical and cognitive decline in older individuals, with a focus on inflammation, oxidative stress, and molecular damage. His influential work has led to notable progress in preventing and treating age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes, and dementia.
Kristen Fortney, PhD
CEO and Co-founder, BioAge
Dr. Fortney is developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. Her company, BioAge, uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.
David Furman, PhD
Associate Professor & Director, Buck Institute & Stanford 1,000 Immunomes
Dr. Furman, an academic and entrepreneur, specializes in advanced statistics, AI, and machine learning for translational medicine. As the Director of the Stanford 1,000 Immunomes Project and an Associate Professor at the Buck Institute for Research on Aging, his research explores the immune system's involvement in aging and age-related diseases, with a particular focus on biomarkers of aging.
Vadim Gladyshev, PhD
Professor of Medicine, Brigham and Women's Hospital
Dr. Gladyshev, a renowned Professor of Medicine at Harvard Medical School and Director of the Center for Redox Medicine at Brigham and Women's, researches aging, lifespan control, and rejuvenation. His focus is on biomarkers of longevity and biological age, such as aging clocks, epigenetic signatures, and the human selenoproteome, revealing insights into aging mechanisms and the dynamic nature of biological aging under varying stress conditions.
Steve Horvath, PhD
Principal Investigator, Altos Labs
Dr. Horvath, a renowned biogerontologist at Altos Labs, specializes in epigenetic biomarkers of aging. His pioneering work includes creating the first saliva epigenetic clock, the pan-tissue Horvath clock, and a universal clock for mammals. With numerous accolades and recognition, he is consistently ranked among the world's most influential scientific researchers.
Jamie Justice, PhD
Assistant Professor, Department of Internal Medicine Section on Gerontology and Geriatrics, Wake Forest School of Medicine
Dr. Justice's research training spans various disciplines, species, and intervention strategies. Her current research includes the both the clinical trial Targeting Aging with MEtformin (TAME), which is designed to facilitate regulatory approval for metformin in order to slow biological aging, as well as investigating the therapeutic potential of targeting the biologic aging hallmark of cellular senescence in humans.
Andrea Maier, PhD, MD
Oon Chiew Seng Professor in Medicine and Healthy Aging, Director Centre for Healthy Longevity at the National University of Singapore, Board Member the Longevity Science Foundation
Dr. Maier focuses on sarcopenia and cellular senescence and their influence on age-related diseases. She serves as a Professor of Gerontology at VU University Amsterdam, The Netherlands, a President of the Australian and New Zealand Society for Sarcopenia and Frailty Research and as an Honorary Professor of Medicine and Aged Care at the University of Melbourne, Australia. She is also an Associate Editor of numerous international journals, such as Frontiers, the Gerontological Society of America, and is on the Editorial Board of ICT&Health.
Joan Mannick, MD
CEO, Tornado Therapeutics
Dr. Joan Mannick is the Chief Executive Officer of Tornado Therapeutics and develops safer and more effective mTOR inhibitors to treat or prevent disease. Dr. Mannick has extensive academic (Harvard Medical School, University of Massachusetts Medical School) and industry expertise (Novartis, Genzyme, resTORbio, Life Biosciences) in multiple therapeutic areas including aging biology.
Mahdi Moqri, PhD MBA
Harvard & Stanford, The Biomakers of Aging Consortium
Dr. Moqri, a joint Research Fellow at Harvard University’s Gladyshev Lab and Stanford University’s Snyder Lab, specializes in researching epigenetic and multi-omics biomarkers of aging. Additionally, he plays a key role in leading the Executive Committee of the Biomarkers of Aging Consortium, dedicated to establishing robust biomarkers for longevity interventions.
Birgit Schilling, PhD
Director of Mass Spectrometry Core, Buck Institute for Research Aging
Dr. Schilling, a Professor at the Buck Institute for Research on Aging and Director of the Mass Spectrometry Core, specializes in biomarkers of aging through proteome analysis. Her research examines protein modifications and their relevance to aging and age-related diseases, employing advanced analytical technologies to gain insights into fundamental aging biology and translational research.
Vittorio Sebastiano, PhD
Associate Professor, Obstetrics and Gynecology, Stanford University / Co-Founder, Turn Biotechnologies
Dr. Sebastiano, an Associate Professor at Stanford University, pioneers cellular reprogramming to reverse aging in human cells and tissues. His research explores leveraging reproduction and embryonic development principles for anti-aging technologies, while leading research at Turn Biotechnologies for age-related disease therapies through transient cell reprogramming.
Michael Snyder, PhD
Principal Investigator, Synder Lab, Stanford University School of Medicine
Dr. Snyder, the Stanford B. Ascherman Professor and Chair of Genetics at Stanford University, is a renowned leader in functional genomics and proteomics. His lab pioneers integrative personal omics profiling (iPOP) using cutting-edge technologies to assess disease risk and monitor personalized medicine. Additionally, Dr. Snyder has founded multiple companies, authored a book on genomics and personalized medicine, and serves on several company boards.
Eric Verdin, MD
President & CEO, Buck Institute for Research Aging
The Verdin Lab at the Buck Institute studies the relationship between aging and the immune system as well as how immune aging is regulated by nutrition. His lab has demonstrated how changes in the relative abundance of key cellular metabolites such as NAD+, acetylcoenzyme A, and the ketone body beta-hydroxybutyrate fluctuate under different nutritional conditions, including obesity, calorie restriction, fasting, time-restricted feeding, ketogenic diet, and how this influences immune responses. He is working on key enzymes regulated by these metabolites, which include sirtuins (NAD+), histone acetyltransferases (acetylcoenzyme A), and histone deacetylases (HDACs).
Alex Zhavoronkov, PhD
Founder & CEO, InSilico Medicine
Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, leads the company in pioneering next-generation generative AI technologies for drug discovery and biomarker development. With substantial funding, global expansion, and numerous partnerships, Insilico has made significant progress, advancing 11 preclinical candidates and entering human clinical trials with AI-discovered targets and designed molecules.
Thanks to our Sponsors
Your 2023 Symposium Chairs (A-Z)
Vadim Gladyshev, PhD
Professor of Medicine, Brigham and Women's Hospital
Andrea Maier, MD
Director Centre for Healthy Longevity at the National University of Singapore
Vittorio Sebastiano, PhD
Associate Professor, Obstetrics and Gynecology, Stanford University / Co-Founder, Turn Biotechnologies
Michael Snyder, PhD
Principal Investigator, Synder Lab, Stanford University School of Medicine
Eric Verdin, MD
President & CEO, Buck Institute for Research Aging
Your 2023 Organizing Committee (A-Z)
Allison Duettmann
President & CEO, Foresight Institute
Nicholas C. Fiorenza
Operations & Project Management, Methuselah Foundation
Dane Gobel
Co-Founder and Program Director, Methuselah Foundation
Chiara Herzog, PhD
Postdoctoral Researcher, Universität Innsbruck
Mahdi Moqri, PhD, MBA
Research Fellow, Aging Research at Stanford School of Medicine & Visiting Scholar, Harvard Medical School.
Jesse Poganik, PhD
Research Fellow, Brigham and Women's Hospital and Harvard Medical School
Your 2023 Volunteers (A-Z)
Ludger Goeminne, PhD
Postdoctoral Researcher, Harvard Medical School & Brigham and Women's Hospital
Alan Tomusiak
PhD Student, Buck Institute
Kejun (Albert) Ying
PhD Student, Harvard University
About the Biomarkers of Aging Consortium
In late 2022, leaders in longevity science were brought together to empower geroscience research. Our growing Consortium comprises academic and industry scientists, clinicians, and regulatory experts working to bring biomarkers of aging to the clinic.
This synergistic combination of expertise is allowing us to take the steps required to establish common ground for our future work, and to realize the great potential of longevity research to improve human lives.
Visit our website to learn more about us and our work:
https://www.agingconsortium.org/
Follow us
Stay informed about the latest research on aging biomarkers and receive updates on the Consortium & Symposium.
Location
The Buck Institute
8001, Redwood Boulevard Novato, CA United States, 94945Registration period
March 17, 2023 - 17:23 until December 5, 2023 - 04:00
Contact us
For any questions about the event, please contact mmoqri@bwh.harvard.edu